Linda Lindström's Group
The Lindström research group’s main scientific interest is in the search of understanding specific patient and tumor characteristics required for the cancer tumor to gain metastatic capacity, in the end responsible for virtually all cancer-related death. We focus on breast cancer with a specific interest in understanding the reasons behind the long-term risk of fatal disease as is seen in majority of patients with breast cancer.
Breast cancer is the most common female cancer in the Western world, comprising almost a third of all cancer cases, and one of the main causes of death in women. It is a diverse disease both considering tumor aggressiveness and time to metastatic disease, which varies from months to several decades after primary diagnosis. In clinical practice a set of breast cancer tumor characteristics (markers) are used to predict prognosis and the benefit from treatment. Among newly diagnosed patients, approximately 70-80% have estrogen receptor (ER)-positive breast cancer and are candidates for anti-hormonal (endocrine) treatment. However, approximately 50% of patients with ER-positive disease do not benefit from endocrine therapy, and approximately one out of four women with breast cancer will die from the disease. It has been shown by us (Esserman and Lindström, JAMA Oncology 2017; Lindström et al, JNCI 2018; Yu and Lindström, JAMA Oncology 2019), and others (Pan et al, NEJM 2018), that patients with ER-positive disease have a limited early but a long-term risk for fatal breast cancer that continues steadily throughout 5 to 25 years after primary diagnosis. However, the biological factors influencing this long-term risk in patients with ER-positive disease are not well understood.
We (Lindström and Bergh et al, JCO 2012) and others have shown that the clinically used breast cancer markers alter their expression throughout tumor progression, and that this influences patient survival. Notably, patients that are primarily ER-positive but loose ER-expression at metastasis have worse survival as compared to patients with stable ER-positive tumor expression. These findings changed clinical management, emphasizing the need for re-examination of tumor characteristics at relapse to improve patient management, and have led to recommendations from ASCO, ESMO, and the Swedish Breast Cancer Group (SweBCG), among others.
What are the likely explanations to our findings? It has been proposed that primary breast tumors may possess intra-tumor heterogeneity with varying metastatic capacity, and that tumors with greater intra-tumor heterogeneity adapt faster as compared to homogeneous tumors. Thus, given that ER-positive breast cancer is associated with a continuous risk of fatal disease, one may hypothesize that having tumor cells with varying characteristics, in contrast to more homogeneous characteristics, may be beneficial for tumor progression and influence patient survival. Indeed, it has been suggested by us (Lindström et al, JNCI 2018) and others that intra-tumor heterogeneity may influence tumor aggressiveness in a variety of cancers. However, it is unknown which tumor characteristics may be clinically important to assess for intra-tumor heterogeneity, for which patient groups (i.e. premenopausal/ postmenopausal patients, or low/ high risk), and whether benefit of treatment is influenced by intra-tumor heterogeneity of certain tumor characteristics.
An example of high and low intra-tumor heterogeneity in two representative patient breast cancer tumors is seen in Figure 1. Figure 1A shows a tumor with strong and homogenous intensity of ER expression (tumor cells have an expression intensity of +2 or +3) i.e. low intra-tumor heterogeneity, whereas in Figure 1B the intensity of tumor cell expression is strong (+3) in a proportion of cells, weaker in other cells (+1, +2), and some cells have no expression of ER (0), i.e. high intra-tumor heterogeneity.
Our long-term goal is to improve the prediction of patients’ risk to die from breast cancer - for aggressive potentially lifesaving treatment in patients with high risk, and to avoid unnecessary side effects in patients with lower risk disease. Risk of fatal breast cancer is of great concern to patients and their families thus better risk prediction would also result in less anxiety.
Main research questions:
- Does intra-tumor heterogeneity influence patient survival and/ or treatment benefit?
- Long-term risk: Which factors are important for the long-term risk of fatal breast cancer disease?
- Endocrine treatment: Identify tumor characteristics and genes expressed that influence the benefit.
- Why do young women diagnosed with breast cancer have poor prognosis?
- Is breast cancer survival inherited?
- Benign breast diseases: Risk by age and hormonal factors, and risk of invasive breast cancer.
Group members
Linda Lindström, Associate Professor and Group Leader
Annelie Johansson, Postdoc
Oscar Danielsson, PhD student
Huma Dar, PhD student
Team Tobin
Nick Tobin, Associate Professor and Team Leader
Miguel Castresana Aguirre, Postdoc
Selected publications
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS
J Clin Oncol 2022 Jul;():JCO2102844
Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden.
Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, Benz CC, Rodriguez-Wallberg KA, Hall P, Czene K, Lindström LS
JAMA Netw Open 2021 06;4(6):e2114716
Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS
JAMA Netw Open 2021 06;4(6):e2114904
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS
JAMA Oncol 2019 Sep;5(9):1304-1309
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ,
J Natl Cancer Inst 2018 07;110(7):726-733
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS
JAMA Oncol 2017 Nov;3(11):1503-1510
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS,
Ann Oncol 2015 Jan;26(1):81-88
Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer.
Lindström LS, Li J, Lee M, Einbeigi Z, Hartman M, Hall P, Czene K
Ann Oncol 2014 Oct;25(10):1966-1972
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J
J Clin Oncol 2012 Jul;30(21):2601-8
Familial concordance in cancer survival: a Swedish population-based study.
Lindström LS, Hall P, Hartman M, Wiklund F, Grönberg H, Czene K
Lancet Oncol 2007 Nov;8(11):1001-6